PF4
Platelet factor 4
Also known as: CXCL4, PLF4_HUMAN, SCYB4
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P02776
- Gene
- PF4
- Ensembl
- ENSG00000163737
- Chromosome
- 4
- Canonical length
- 101 aa
- Protein class
- Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
- Quaternary structure
- Homotetramer
OverviewNCBI Gene
This gene encodes a member of the CXC chemokine family. This chemokine is released from the alpha granules of activated platelets in the form of a homotetramer which has high affinity for heparin and is involved in platelet aggregation. This protein is chemotactic for numerous other cell type and also functions as an inhibitor of hematopoiesis, angiogenesis and T-cell function. The protein also exhibits antimicrobial activity against Plasmodium falciparum. [provided by RefSeq, Oct 2014]
Canonical amino-acid sequenceUniProt
101 residues, UniProt reviewed canonical sequence.
>P02776|PF4
1 MSSAAGFCAS RPGLLFLGLL LLPLVVAFAS AEAEEDGDLQ CLCVKTTSQV RPRHITSLEV
61 IKAGPHCPTA QLIATLKNGR KICLDLQAPL YKKIIKKLLE SLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PF4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.49
- Highest tissue expression
- 28 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 28 nTPM
- spleen: 9.8 nTPM
- lung: 3.2 nTPM
- placenta: 1.6 nTPM
- tongue: 1.4 nTPM
- gallbladder: 0.5 nTPM
Single-cell type
- platelets: 1,437 nCPM
- megakaryocytes: 940 nCPM
- megakaryocyte progenitors: 48 nCPM
- erythrocytes: 1.9 nCPM
- neutrophil progenitors: 1 nCPM
- pdcs: 0.7 nCPM
Immune cell
- total PBMC: 3.1 nTPM
- neutrophil: 2 nTPM
- basophil: 0.4 nTPM
- plasmacytoid DC: 0.2 nTPM
- T-reg: 0.2 nTPM
- classical monocyte: 0 nTPM
Brain region
- cerebral cortex: 1.9 nTPM
- choroid plexus: 0.6 nTPM
- white matter: 0.4 nTPM
- basal ganglia: 0.3 nTPM
- medulla oblongata: 0.3 nTPM
- pons: 0.3 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PF4.
Disease | AutoantibodyPubMed
Conditions in which antibodies against PF4 are reported. Each links to that disease's full target list.
- Thrombocytopenia 34
- COVID-19 23
- Thrombosis 21
- Purpura, Thrombocytopenic, Idiopathic 16
- Purpura, Thrombotic Thrombocytopenic 3
Showing 5 of 6 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for PF4 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
60 publications
- Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.
2021 · N Engl J Med · RCR 116.3 · 1,751 citations - Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia.
2021 · Blood · RCR 15.4 · 267 citations - Autoimmune heparin-induced thrombocytopenia.
2017 · J Thromb Haemost · RCR 11.6 · 302 citations - Prothrombotic immune thrombocytopenia after COVID-19 vaccination.
2021 · Blood · RCR 8.7 · 140 citations - Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection.
2021 · J Autoimmun · RCR 8 · 122 citations
Show 20 more of 60 total
- Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia.
2021 · Haematologica · RCR 6.9 · 110 citations - Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia.
1996 · Blood · RCR 5.7 · 181 citations - Perspectives on vaccine induced thrombotic thrombocytopenia.
2021 · J Autoimmun · RCR 2.9 · 48 citations - Cerebral venous sinus thrombosis and thrombocytopenia due to heparin-independent anti-PF4 antibodies after adenovirus infection.
2024 · Haematologica · RCR 2.8 · 17 citations - Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia.
2025 · N Engl J Med · RCR 2.3 · 7 citations - Persistence of anti-platelet factor 4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis for 3 years.
2025 · J Thromb Haemost · RCR 2.2 · 7 citations - False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus.
2009 · J Thromb Haemost · RCR 2.2 · 71 citations - Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature.
2020 · Int J Mol Sci · RCR 2.1 · 43 citations - Characterization of New Monoclonal PF4-Specific Antibodies as Useful Tools for Studies on Typical and Autoimmune Heparin-Induced Thrombocytopenia.
2021 · Thromb Haemost · RCR 2 · 30 citations - Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation.
2021 · Diabetes Metab Syndr · RCR 1.8 · 24 citations - Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies.
2017 · Br J Haematol · RCR 1.8 · 46 citations - Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly.
2007 · J Clin Apher · RCR 1.5 · 57 citations - Frequency and Clinical Impact of Platelet Factor 4-Specific Antibodies in Patients Undergoing Extracorporeal Membrane Oxygenation.
2019 · Thromb Haemost · RCR 1.4 · 22 citations - Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation.
2000 · Br J Haematol · RCR 1.4 · 55 citations - Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex.
2008 · Kidney Int · RCR 1.1 · 29 citations - The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis.
2007 · Thromb Res · RCR 0.9 · 28 citations - Structural Characterization of a Pathogenic Antibody Underlying Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT).
2024 · Anal Chem · RCR 0.8 · 5 citations - New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis.
2021 · Antibodies (Basel) · RCR 0.8 · 12 citations - Virtual Screening of Protein Data Bank via Docking Simulation Identified the Role of Integrins in Growth Factor Signaling, the Allosteric Activation of Integrins, and P-Selectin as a New Integrin Ligand.
2023 · Cells · RCR 0.7 · 5 citations - Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4.
2013 · J Biol Chem · RCR 0.7 · 21 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.73
- gnomAD pLI
- 0.04
- gnomAD missense Z
- 0.26
- DepMap mean gene effect
- -0.24
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adenylate cyclase-activating G protein-coupled receptor signaling pathway
- antimicrobial humoral immune response mediated by antimicrobial peptide
- cellular response to lipopolysaccharide
- cytokine-mediated signaling pathway
- defense response to protozoan
- inflammatory response
- killing by host of symbiont cells
- leukocyte chemotaxis
- monocyte chemotaxis
- negative regulation of angiogenesis
- negative regulation of blood coagulation
- negative regulation of extrinsic apoptotic signaling pathway in absence of ligand
- negative regulation of megakaryocyte differentiation
- negative regulation of MHC class II biosynthetic process
- neutrophil chemotaxis
- platelet activation
- positive regulation of gene expression
- positive regulation of macrophage derived foam cell differentiation
- positive regulation of macrophage differentiation
- positive regulation of transcription by RNA polymerase II
- positive regulation of tumor necrosis factor production
- regulation of cell population proliferation
Molecular functions
- chemokine activity
- CXCR chemokine receptor binding
- CXCR3 chemokine receptor binding
- heparin binding
- receptor ligand activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of PF4 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PF4 as an antibody target. Whether an autoantibody or antibody against PF4 could matter depends on whether native PF4 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PF4 is annotated as secreted, so native PF4 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label PF4 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...